Learn More
OBJECTIVE Rapidly increasing colorectal cancer (CRC) incidence in Malaysia and the introduction of cutting edge new treatments, which prolong survival, mean that treatment outcome measures meed to be evaluated, including consideration of patient's quality of life (QoL) assessment. There are limited data on QoL in CRC patients, especially in Malaysia.(More)
Introduction The introduction of monoclonal antibody in the management of Colorectal Cancer (CRC) in the rapidly rising healthcare cost environment prompt a proper evaluation of its cost effectiveness especially to the local setting. The rising incidence of CRC in Malaysia also justifies a detailed evaluation on its economic impact. This study aims to(More)
  • 1